

AMICUS THERAPEUTICS INC
 Form 3
 May 30, 2007

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0104
 Expires: January 31, 2005
 Estimated average burden hours per response... 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
 Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *		2. Date of Event Requiring Statement	3. Issuer Name and Ticker or Trading Symbol	
Â Bloch Stephen M		(Month/Day/Year)	AMICUS THERAPEUTICS INC [FOLD]	
(Last)	(First)	(Middle)	05/30/2007	
C/O CANAAN PARTNERS,Â 285 RIVERSIDE AVENUE, SUITE 250			4. Relationship of Reporting Person(s) to Issuer	5. If Amendment, Date Original Filed(Month/Day/Year)
(Street)			(Check all applicable)	
WESTPORT,Â CTÂ 06880			<input checked="" type="checkbox"/> Director	<input checked="" type="checkbox"/> 10% Owner
(City)	(State)	(Zip)	<input type="checkbox"/> Officer	<input type="checkbox"/> Other
			(give title below) (specify below)	
			6. Individual or Joint/Group Filing(Check Applicable Line)	
			<input checked="" type="checkbox"/> Form filed by One Reporting Person	
			<input type="checkbox"/> Form filed by More than One Reporting Person	

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
------------------------------------	--	---	--

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)	3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of	

Edgar Filing: AMICUS THERAPEUTICS INC - Form 3

				Shares		or Indirect (1) (Instr. 5)	
Series B Convertible Preferred Stock	05/04/2004	Â (3)	Common Stock	449,110 (3)	\$ 0 (3)	I	Canaan Equity III, L.P. (1)
Series B Convertible Preferred Stock	05/04/2004	Â (3)	Common Stock	16,771 (3)	\$ 0 (3)	I	Canaan Equity III Entrepreneurs, LLC (2)
Series B Convertible Preferred Stock	03/24/2005	Â (3)	Common Stock	449,110 (3)	\$ 0 (3)	I	Canaan Equity III, L.P. (1)
Series B Convertible Preferred Stock	03/24/2005	Â (3)	Common Stock	16,771 (3)	\$ 0 (3)	I	Canaan Equity III Entrepreneurs, LLC (2)
Series C Convertible Preferred Stock	08/16/2005	Â (3)	Common Stock	437,415 (3)	\$ 0 (3)	I	Canaan Equity III, L.P. (1)
Series C Convertible Preferred Stock	08/16/2005	Â (3)	Common Stock	16,334 (3)	\$ 0 (3)	I	Canaan Equity III Entrepreneurs, LLC (2)
Series C Convertible Preferred Stock	04/17/2006	Â (3)	Common Stock	437,415 (3)	\$ 0 (3)	I	Canaan Equity III, L.P. (1)
Series C Convertible Preferred Stock	04/17/2006	Â (3)	Common Stock	16,334 (3)	\$ 0 (3)	I	Canaan Equity III Entrepreneurs, LLC (2)
Series D Convertible Preferred Stock	09/13/2006	Â (3)	Common Stock	98,029 (3)	\$ 0 (3)	I	Canaan Equity III, L.P. (1)
Series D Convertible Preferred Stock	09/13/2006	Â (3)	Common Stock	3,660 (3)	\$ 0 (3)	I	Canaan Equity III Entrepreneurs, LLC (2)
Series D Convertible Preferred Stock	09/13/2006	Â (3)	Common Stock	98,029 (3)	\$ 0 (3)	I	Canaan Equity III, L.P. (1)
Series D Convertible Preferred Stock	09/13/2006	Â (3)	Common Stock	3,660 (3)	\$ 0 (3)	I	Canaan Equity III Entrepreneurs, LLC (2)
Series B Convertible Preferred Stock Warrant (right to buy)	05/04/2004	Â (4)	Series B Convertible Preferred Stock	13,669	\$ 6.375	I	Canaan Equity III, L.P. (1)
Series B Convertible Preferred Stock Warrant (right to buy)	05/04/2004	Â (4)	Series B Convertible Preferred Stock	510	\$ 6.375	I	Canaan Equity III Entrepreneurs, LLC (2)

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Bloch Stephen M C/O CANAAN PARTNERS 285 RIVERSIDE AVENUE, SUITE 250 WESTPORT, CT 06880	X	X		

Signatures

/s/ Stephen Bloch 05/30/2007

**Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
 - (1) L.P. The reporting person is a member of Canaan Equity Partners III, LLC, which is the general partner of Canaan Equity III, L.P. Voting and investment power over these shares is exercised by Canaan Equity Partners III, LLC in its role as general partner of Canaan Equity III, L.P. The reporting person disclaims beneficial ownership of these shares except to the extent of his proportionate pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the shares for purposes of Section 16 or for any other purpose.

The reporting person is a member of Canaan Equity Partners III, LLC, which is the general partner of Canaan Equity III Entrepreneurs, LLC Voting and investment power over these shares is exercised by Canaan Equity Partners III, LLC in its role as manager of Canaan Equity III Entrepreneurs, LLC The reporting person disclaims beneficial ownership of these shares except to the extent of his proportionate pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the shares for purposes of Section 16 or for any other purpose.
 - (2) Each share is convertible and will automatically convert on a 1-for-1 basis into the Issuer's common stock upon the closing of the Issuer's initial public offering of common stock pursuant to an effective registration statement filed with the U.S. Securities and Exchange Commission. These shares have no expiration date.
 - (3) The warrants to purchase Series B Convertible Preferred Stock will be automatically net exercised immediately prior to the closing of the Issuer's initial public offering.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.